anti sars-cov-2 equine hyperimmune serum
Animal productexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Mar 29, 2021 (NCT04838821)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
immunity, passive - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04838821 | Phase 2/Phase 3 (Phase 3) | Mar 29, 2021 | Caja Costarricense de Seguro Social, Government of Costa Rica, Universidad de Costa Rica |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Caja Costarricense de Seguro Social | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Government of Costa Rica | Government | 1 | 0 | 1 | 2021 |
| Universidad de Costa Rica | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1